Skip to content

Mometasone

DRUG16 trials

Sponsors

Insmed Inc., HAL Allergy B.V., Eli Lilly & Co., Universitair Ziekenhuis Gent, Organon and Co

Conditions

Allergic RhinitisAsthmaChronic Rhinosinusitis With Nasal Polyps (CRSwNP)Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) AllergyOtitis Media With EffiusionPerennial Allergic RhinitisPerennial Allergic Rhinitis (PAR)

Phase 1

Phase 2

Phase 3

A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
CompletedNCT00783224
Organon and CoPerennial Allergic Rhinitis
Start: 2005-09-30End: 2005-12-31Updated: 2022-02-09
Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
CompletedNCT01401465
Sumitomo Pharma America, Inc.Perennial Allergic Rhinitis
Start: 2011-07-31End: 2011-11-30Updated: 2013-04-30
Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children
CompletedNCT02541760
Hormozgan University of Medical SciencesOtitis Media With Effiusion
Start: 2014-04-30End: 2015-04-30Updated: 2015-09-04
Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis
CompletedNCT05311475
SandozSeasonal Allergic Rhinitis
Start: 2022-04-04End: 2023-06-20Updated: 2023-07-11
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects with Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy
Active, not recruitingCTIS2023-504942-75-01
HAL Allergy B.V.Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy
Start: 2024-08-22Target: 582Updated: 2025-12-16
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants with Chronic Rhinosinusitis with Nasal Polyps on Background Intranasal Corticosteroids
RecruitingCTIS2023-508760-29-00
Eli Lilly & Co.Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Start: 2024-10-21Target: 231Updated: 2025-09-22
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis
RecruitingCTIS2023-508817-18-00
Eli Lilly & Co.Perennial Allergic Rhinitis (PAR)
Start: 2024-10-08Target: 258Updated: 2025-10-20

Phase 4

Related Papers